Adjust Share
I can tell you where it all started because I remember the moment exactly. It was late and I’d just finished the novel I’d been reading. A few more pages would send me off to sleep, so I went in search of a short story. They aren’t hard to come by around here; my office is made up of piles of books, mostly advance-reader copies that have been sent to me in hopes I’ll write a quote for the jacket. They arrive daily in padded mailers novels, memoirs, essays, histories things I never requested and in most cases will never get to. On this summer night in 2017, I picked up a collection called
Posted on 755
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).
The ongoing, open-label, multicenter trial is a Phase 1/1b study evaluating the safety profile and clinical activity of AB680 in combination with nab-paclitaxel plus gemcitabine (NP/Gem) and zimberelimab, an anti-PD-1 antibody, as a first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).